Alpha Paradigm Partners, LLC Editas Medicine, Inc. Transaction History

Alpha Paradigm Partners, LLC

  • $239 Million
  • Q4 2022

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $345,915 - $552,440
28,447 New
28,447 $348,000
Q3 2021

Nov 15, 2021
SELL
$39.27 - $72.94 $655,612 - $1.22 Million
-16,695 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$31.29 - $56.64 $522,386 - $945,604
16,695 New
16,695 $946 Million

Others Institutions Holding EDIT

# of Institutions
240
Shares Held
56.5M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $85.9M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Alpha Paradigm Partners, LLC Portfolio

Follow Alpha Paradigm Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Paradigm Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Paradigm Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email